<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: <z:chebi fb="0" ids="26274,32874">Prolyl</z:chebi> hydroxylase (PHD) hydroxylates <z:mp ids='MP_0005039'>hypoxia</z:mp> inducible factor (HIF) alpha, leading to HIFalpha degradation </plain></SENT>
<SENT sid="1" pm="."><plain>The PHD family comprises PHD1, PHD2, and PHD3 </plain></SENT>
<SENT sid="2" pm="."><plain>The enzymatic activity of PHDs is <z:chebi fb="0" ids="15379">O(2)</z:chebi>-dependent, so PHDs are believed to be oxygen sensors as well as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors </plain></SENT>
<SENT sid="3" pm="."><plain>However, the expression pattern of PHDs in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and the correlation between their expression level and <z:mp ids='MP_0002006'>tumorigenesis</z:mp> is unclear </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We determined the expression of PHDs in 60 human primary colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> tissues, paired with <z:mpath ids='MPATH_458'>normal</z:mpath> colorectal tissues </plain></SENT>
<SENT sid="5" pm="."><plain>PHD3 expression levels were knocked down using small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> (siRNA); cells were analyzed by immunoblotting, immunoprecipitation, and histochemical analyses </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> was analyzed in nu/nu mice </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Expression of PHD3 is decreased in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues </plain></SENT>
<SENT sid="8" pm="."><plain>Decreased expression of PHD3 is associated with higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>PHD3 inhibits phosphorylation of inhibitor of kappaB (IkappaB) kinase (IKK) beta and activation of (NF) kappaB, independent of its hydroxylase activity </plain></SENT>
<SENT sid="10" pm="."><plain>PHD3 associates with IKKbeta but does not target it for destruction; instead, PHD3 blocks the interaction between IKKbeta and Hsp90 that is required for phosphorylation of IKKbeta </plain></SENT>
<SENT sid="11" pm="."><plain>Knockdown of PHD3 increased resistance of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to the effects of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha and <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: PHD3 appears to be a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells that inhibits IKKbeta/NF-kappaB signaling, independent of its hydroxylase activity </plain></SENT>
<SENT sid="13" pm="."><plain>Activation of NF-kappaB has been observed in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Determination of PHD3 status could aid targeted therapy selection for patients with <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> that have increased NF-kappaB activity </plain></SENT>
</text></document>